Protective efficacy of a SARS-CoV-2 DNA vaccine in wild-type and immunosuppressed Syrian hamsters
Abstract A worldwide effort to counter the COVID-19 pandemic has resulted in hundreds of candidate vaccines moving through various stages of research and development, including several vaccines in phase 1, 2 and 3 clinical trials. A relatively small number of these vaccines have been evaluated in SA...
Guardado en:
Autores principales: | Rebecca L. Brocato, Steven A. Kwilas, Robert K. Kim, Xiankun Zeng, Lucia M. Principe, Jeffrey M. Smith, Jay W. Hooper |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/021913bd329840d1928fea1d69b27f9e |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Comparison of transcriptional responses between pathogenic and nonpathogenic hantavirus infections in Syrian hamsters using NanoString.
por: Rebecca L Brocato, et al.
Publicado: (2021) -
MVA vector expression of SARS-CoV-2 spike protein and protection of adult Syrian hamsters against SARS-CoV-2 challenge
por: Clement A. Meseda, et al.
Publicado: (2021) -
Vaccinia virus-based vaccines confer protective immunity against SARS-CoV-2 virus in Syrian hamsters.
por: Rakesh Kulkarni, et al.
Publicado: (2021) -
Ad26.COV2.S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory disease
por: Joan E. M. van der Lubbe, et al.
Publicado: (2021) -
Orally delivered MK-4482 inhibits SARS-CoV-2 replication in the Syrian hamster model
por: Kyle Rosenke, et al.
Publicado: (2021)